Everest Medicines Enters Commercialization License Agreement with Mabworks for Bejescin® in the Asia-Pacific Market
Everest Medicines has obtained exclusive rights for the clinical development and commercialization of Bejescin® (MIL62, Obinutuzumab beta Injection) across the Asia-Pacific region, including Southeast Asia, India, South Korea, Australia, New...